EP3524261
EXENDÍN TIL AÐ MEÐHÖNDLA SYKURSÝKI OG DRAGA ÚR LÍKAMSÞYNGD
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
18.8.2006EP published:
13.12.2023EP application number:
19163698.4
EP translation filed:
9.1.2024Grant published:
15.2.2024EPO information:
European Patent Register
Max expiry date:
17.8.2026Expiry date:
17.8.2026
Title in English:
EXENDIN FOR USE IN TREATING DIABETES AND REDUCING BODY WEIGHTLanguage of the patent:
English
Timeline
Today
18.8.2006EP application
13.12.2023EP Publication
9.1.2024Translation submitted
15.2.2024Registration published
17.8.2026Expires
Owner
Name:
Amylin Pharmaceuticals, LLCAddress:
9360 Towne Centre Drive, San Diego, CA 92121, US
Name:
AstraZeneca Pharmaceuticals LPAddress:
1800 Concord Pike, Wilmington, DE, US
Inventor
Name:
Fineman, MarkAddress:
San Diego, CA California 92121, US
Name:
Macconell, LeighAddress:
San Diego, CA California 92121, US
Name:
Taylor, KristinAddress:
San Diego, CA California 92121, US
Agent
Name:
G.H. Sigurgeirsson ehf.Address:
Borgartúni 26, 105, Reykjavík,
Priority
Number:
77921606 PDate:
3.3.2006Country:
US
Number:
70960405 PDate:
19.8.2005Country:
US
Classification
Categories:
A61K 38/26, A61K 9/00, A61P 3/10, A61P 3/04
Annual fees
Number
Paid
Expires
Payer
Number: 19
Paid: 9.7.2024
Expires: 17.8.2025
Payer: Árnason Faktor ehf.
Number: 20
Paid: 12.8.2025
Expires: 17.8.2026
Payer: Árnason Faktor ehf.